Por: The Boston Globe Business September 06, 2024
WASHINGTON — Federal regulators responsible for the safety of the US drug supply are still struggling to get back to where they were in 2019, before the COVID-19 pandemic upended factory inspections in the United States and across the world, the Associated Press has found.An AP analysis of Food and Drug Administration data shows that agency staffers have not returned to roughly 2,000 pharmaceutical manufacturing firms to conduct surveillance... + full article
The Advocate USA Entertainment January 30, 2024
Put down the pruning shears.With recent freezing temperatures across Louisiana and a dose of ice, sleet and even snow in some places, all of our gardens probably have suffered some damage. It’s tempting to rush outside to prune away unsightly damaged sections or even rip out... + más
'Frustration' fuels Broncos' sideline blowup in loss | ESPN
Did Martha Washington really name a cat after Alexander Hamilton? | The Boston Globe
Time USA Health April 12, 2023
Now that a Texas judge has ruled that the U.S. Food and Drug Administration (FDA)’s , what happens to the supply of the drug? The judge gave the Department of Justice (DOJ), which represents the FDA, until Apr. 14 to file an appeal before the suspension of the drug takes... + más
What Are the Duties of A Trustee? | Forbes
NFL Week 17 playoff picture and clinching scenarios: Bucs win NFC South; Giants clinch wild card | ESPN
Time USA Health April 07, 2023
WASHINGTON — The Food and Drug Administration on Thursday ordered the immediate market withdrawal of a drug intended to prevent premature births, which has remained available for years despite data showing it doesn’t help pregnant women. The decision follows repeated efforts... + más
FDA holds hearing to remove pregnancy drug from market, company pushes back | WGN-TV
Maker of unproven birth drug Makena to pull from US market | ABC News
ABC News USA Health March 16, 2023
A U.S. Food and Drug Administration analysis did not find a clear association between the COVID-19 antiviral drug , .Rebound rates are around the same in people who took the drug and those who didn't, the study said. It's the first time the FDA has weighed in on... + más
No clear association between Paxlovid and COVID-19 rebound, FDA says | ABC7
COVID-19 pill Paxlovid moves closer to full FDA approval | Orlando Sentinel
Politico USA Health December 30, 2022
The FDA’s collaboration with Biogen, the maker of a controversial Alzheimer’s drug, before it granted the product accelerated approval was “atypical” and ran afoul of the agency’s protocol for documenting interactions with drug companies, according to a joint House... + más
Alzheimer's drug approval by FDA 'rife with irregularities,' probe finds | Los Angeles Times
Probe: Alzheimer's drug approval 'rife with irregularities' | ABC News
Los Angeles Times USA Science December 30, 2022
The Food and Drug Administration’s contentious approval of a questionable Alzheimer’s drug took another hit Thursday as congressional investigators called the process “rife with irregularities.” The 18-month investigation by two House committees detailed “atypical... + más
Probe: Alzheimer's drug approval 'rife with irregularities' | WPLG Local 10
ABC News USA Health September 30, 2022
WASHINGTON -- A much-debated drug for Lou Gehrig’s disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.Amylyx Pharmaceuticals said the Food and... + más
Highly debated Amylyx Pharmaceuticals ALS drug wins FDA approval | New York Post
ALS drug wins FDA approval despite questionable data | WPLG Local 10
About iurex | Privacy Policy | Disclaimer |